Japan approves iron deficiency drug from Pharmacosmos
With the approval from the Japanese health authorities, Danish pharmaceutical firm Pharmacosmos can now initiate the launch of its iron deficiency anemia treatment in Japan.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Five years after Danish Pharmacosmos entered a strategic collaboration with Japanese partner Nippon Shinyaku on the launch of Monover (ferric derisomaltose) in Japan, the two parties can now initiate the marketing efforts in the country.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.